Abstract

It's Time for a New Philosophy

Author(s): Brunner Scott

Issue: Sep/Oct 2021 - Volume 25, Number 5

Page(s): 386-387

Download in electronic PDF format for $75
  • It's Time for a New Philosophy Page 1
  • It's Time for a New Philosophy Page 2

Abstract

Related Keywords

  • U.S. Food and Drug Administration
  • FDA
  • drug supply chains
  • covid-19 pandemic
  • temporary guidance
  • labeling standards
  • registration of 503A compounding pharmacies
  • adverse event reporting

Related Categories

  • BUSINESS
  • LEGAL
  • ADVERSE DRUG EVENTS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2021
Pg. 386-387
It's Time for a New Philosophy
Author(s): Brunner Scott
Jul/Aug 2020
Pg. 287-295
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
Author(s): McElhiney Linda F
Mar/Apr 2017
Pg. 95-102
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Jul/Aug 2020
Pg. 268
PreScription: COVID-19 and Compounding Pharmacists
Author(s): Allen Loyd V Jr
Mar/Apr 2022
Pg. 100-109
Allowing Compounding Pharmacies to Address Drug Shortages
Author(s): Broughel James
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Sep/Oct 2014
Pg. 379-380
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Author(s): Blankenship Cynthia E
Mar/Apr 2021
Pg. 109-113
Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic
Author(s): Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B
Jul/Aug 2021
Pg. 296-297
A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot
Author(s): Brunner Scott
Jan/Feb 2019
Pg. 32-33
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jul/Aug 2007
Pg. 326-327
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Author(s): Kupiec Tom, Kemp Jesse
May/Jun 2014
Pg. 208
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Author(s): Miller David G
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr
Jan/Feb 2023
Pg. 12-21
Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants
Author(s): Riepl Mike
Nov/Dec 2015
Pg. 449-450
International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Good and Drug Administration's Misguided Veterminary Guidance
Author(s): Miller David G
Nov/Dec 2016
Pg. 457-458
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Author(s):